Efficacy and Safety of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Systematic Literature Review
DOI:
https://doi.org/10.32635/2176-9745.RBC.2024v70n1.4482Keywords:
Leukemia, Biphenotypic, Acute, Antibodies, Bispecific, Evaluación de la Tecnología Biomédica, ReviewAbstract
Introduction: The conventional treatment options for acute lymphoblastic leukemia (ALL) are chemotherapy, blood transfusion, and bone marrow transplant. Blinatumomab is a novel form of treatment that uses bispecific antibody technology to fight ALL. Objective: Systematic literature review to evaluate the efficacy and safety of blinatumomab for the treatment of patients with ALL. Method: Studies on the topic were searched in the Cochrane, Embase, LILACS and PubMed databases. The Rayyan and EndNote tools were used for reference management. The selection, extraction and quality assessment stages were conducted in pairs and disagreements were resolved by consensus. The quality of the evidence obtained and the risk of bias were assessed using Cochrane's GRADE and RoB 2 tools. Results: Five scientific articles referred to three multicenter and international randomized clinical trials were included for analysis. The results related to overall survival, progression-free survival and adverse events were better in the blinatumomab group compared with conventional chemotherapy. The analysis of risk of bias raised some concerns for the progression-free survival and adverse events outcomes, mainly due to the blinding of participants, which also determined that the degree of certainty of the evidence was classified as moderate. Conclusion: Increased survival and lower rate of adverse events were observed for the blinatumomab group, suggesting that it is more effective and safer when compared to conventional chemotherapy for the treatment of ALL.
Downloads
References
Instituto Nacional de Câncer. ABC do câncer: abordagens básicas para o controle do câncer. 6. ed. rev. atual. Rio de Janeiro: INCA; 2020.
Associação Brasileira de Linfoma e Leucemia [Internet]. São Paulo: Revista ABRALE; 2019. Mota T. Guia das leucemias; 2019 abr 4. [acesso 2023 fev 21]. Disponível: https://revista.abrale.org.br/saude/2019/04/guia-das-leucemias/
Tognon R, Nunes NS, Castro FA. Apoptosis deregulation in myeloproliferative neoplasms. Einstein. 2013;11(4):540-4. doi: https://doi.org/10.1590/S1679-45082013000400025 DOI: https://doi.org/10.1590/S1679-45082013000400025
Instituto Nacional de Câncer. Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2022.
Ministério da Saúde (BR). Portaria n° 705, de 12 de agosto de 2014. Aprova as Diretrizes Diagnósticas e Terapêuticas da Leucemia Mieloide Aguda do Adulto. Diário Oficial da União, Brasília, DF. 2014 ago 13; Seção I.
International Agency for Research on Cancer. [Internet]. Lyon: IARC; c2020. Leukaemia. [acesso 2022 mar 09]. Disponível em: https://gco.iarc.fr/today/data/factsheets/cancers/36-Leukaemia-fact-sheet.pdf
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. doi: https://doi.org/10.1038/bcj.2017.53 DOI: https://doi.org/10.1038/bcj.2017.53
Mullighan C, Goorha S, Radtke I, et al. Análise genômica ampla de alterações genéticas na leucemia linfoblástica aguda. Natureza. 2007;446:758-64. doi: https://doi.org/10.1038/nature05690 DOI: https://doi.org/10.1038/nature05690
Associação Brasileira de Linfoma e Leucemia [Internet]. São Paulo: ABRALE; c2023. Quais os tratamentos para a Leucemia Linfóide Aguda? [acesso 2023 fev 21]. Disponível: https://www.abrale.org.br/doencas/leucemia/lla/tratamentos/#1583784552697-b5464ca0-8ae1fb35-83e5e4f6-4203cd9c-df38
Teachey DT, Hunger SP. Immunotherapy for ALL takes the world by storm. Nat Rev Clin Oncol. 2017;15(2):69-70. DOI: https://doi.org/10.1038/nrclinonc.2017.176
Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific t-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101(5):634-45. doi: https://doi.org/10.1002/cpt.651 DOI: https://doi.org/10.1002/cpt.651
Agência Nacional de Vigilância Sanitária (BR). Brasília, DF: ANVISA; c2022. Consultas: blincyto. [acesso 2022 dez 20]. Disponível em: https://consultas.anvisa.gov.br/#/medicamentos/25351769941201466/
Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317(9):1255-60. DOI: https://doi.org/10.1016/j.yexcr.2011.03.010
University of York. Centre for Reviews and Dissemination. New York: University of York; 2019. PROSPERO - International prospective register of systematic reviews. 2023. [acesso 2023 ago 31]. Disponível em: https://www.crd.york.ac.uk/PROSPERO/
Ministério da Saúde (BR). Diretrizes metodológicas: elaboração de revisão sistemática e meta-análise de ensaios clínicos randomizados. Brasília, DF: Ministério da Saúde; 2021.
Page MJ, McKenzie JE, Bossuyt PM, et al. A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas. Rev Panam Salud Publica. 2022;46:e112. doi: https://doi.org/10.26633%2FRPSP.2022.112 DOI: https://doi.org/10.26633/RPSP.2022.112
EndNote [Internet]. Filadélfia: Clarivate; c2023. [acesso 2021 set 10]. Disponível em: https://endnote.com/
Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. doi: https://doi.org/10.1186/s13643-016-0384-4 DOI: https://doi.org/10.1186/s13643-016-0384-4
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: https://doi.org/10.1136/bmj.l4898 DOI: https://doi.org/10.1136/bmj.l4898
GRADEpro GDT: GRADEpro guideline development tool [Internet]. Hamilton: McMaster University and Evidence Prime; 2022. [acesso em 2023 ago 23]. Disponível em: https://www.gradepro.org/
Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-Cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):833-42. doi: https://doi.org/10.1001/jama.2021.0669 DOI: https://doi.org/10.1001/jama.2021.0669
Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-47. doi: https://doi.org/10.1056/nejmoa1609783 DOI: https://doi.org/10.1056/NEJMoa1609783
Locatelli F, Zugmaier G, Rizzari C, et al. Effect of Blinatumomab vs Chemotherapy on event-free survival among children with high-risk first-relapse B-Cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843-54. doi: https://doi.org/10.1001/jama.2021.0987 DOI: https://doi.org/10.1001/jama.2021.0987
Stein AS, Larson RA, Schuh AC, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018;2(13):1522-31. doi: https://doi.org/10.1182/bloodadvances.2018019034 DOI: https://doi.org/10.1182/bloodadvances.2018019034
Topp MS, Zimmerman Z, Cannell P, et al. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018;131(26):2906-14. doi: https://doi.org/10.1182/blood-2017-09-804658 DOI: https://doi.org/10.1182/blood-2017-09-804658
Drugsite Trust [Internet]. New Zealand: Drugsite Trust; 2000-2024. Blincyto FDA Approval History. 2023 [acesso 2023 mar 20]. Disponível em: https://www.drugs.com/history/blincyto.html
Lynch SS. Manual MSD versão saúde para a família: eficácia e segurança do medicamento [Internet]. Nova Jersey: Merck & Co, Inc.; c2022. [acesso 2022 jun 12]. Disponível em: https://www.msdmanuals.com/pt-br/casa/medicamentos/considera%C3%A7%C3%B5es-gerais-sobre-medicamentos/efic%C3%A1cia-e-seguran%C3%A7a-do-medicamento
Conselho Nacional de Incorporação de Tecnologias no Sistema Único de Saúde (BR). Relatório de recomendação: medicamento Blinatumomabe para leucemia linfoblástica aguda (LLA) B derivada pediátrica em primeira recidiva medular de alto risco. Brasília, DF: MS; 2022. Disponível em: https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2022/20220401_relatorio_cp_11_blinatumomabe_leucemia_linfoblastica_aguda.pdf
Ministério da Saúde (BR). Portaria SCTIE/MS Nº 51, de 1º de junho de 2022. Torna pública a decisão de incorporar, no âmbito do Sistema Único de Saúde - SUS, o blinatumomabe para leucemia linfoblástica aguda (LLA) B derivada pediátrica em primeira recidiva medular de alto risco, conforme protocolo estabelecido pelo Ministério da Saúde. Brasília, DF. 2022 jun 3; seção I:78.
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
